Dr. Edwin Merrifield, Director of Biomarker Technical Operations at Pacific Biomarkers, Inc. (OTCBB: PBMC), a provider of biomarker laboratory services to the pharmaceutical, biotechnology and diagnostics industries, has contributed an article on the value of immunogenicity testing to the September 1 issue of Genetic Engineering & Biotechnology News (GEN)
SEATTLE, WA – September 7, 2010 —Dr. Edwin Merrifield, Director of Biomarker Technical Operations at Pacific Biomarkers, Inc. (OTCBB: PBMC), a provider of biomarker laboratory services to the pharmaceutical, biotechnology and diagnostics industries, has contributed an article on the value of immunogenicity testing to the September 1 issue of Genetic Engineering & Biotechnology News (GEN).
In the article, titled “Immunogenicity Testing Proves Invaluable: Measuring Potential Responses Serves as Key Step in Guiding Development of Novel Drugs,” Dr. Merrifield notes that biopharmaceutical companies hope to introduce a new generation of biologic drugs over the next decade. Since most biologics elicit some level of antibody response that could lead to potentially serious side effects, it is necessary to screen for immunogenicity and to quantify and characterize the antibody response.
“The risk of immunogenicity needs to be considered individually for each indication and patient population,” writes Dr. Merrifield in the article. “Testing for immunogenicity is an important component of any drug discovery program and is sure to play a key role in the development of future pharmaceuticals.”
Access the full text of the article here.
About Pacific Biomarkers, Inc.
Established in 1989, PBI provides biomarker laboratory services and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The Company provides expert services in the areas of cardiovascular and musculoskeletal diseases, diabetes, obesity, and nutrition. The PBI laboratory is accredited by the College of American Pathologists, New York State, and the Lipid Standardization Program. PBI’s clients include many of the world’s largest pharmaceutical, biotech, and diagnostic companies. PBI also provides clinical biomarker services focusing on the emerging field of biomarker assay development and testing. Services include validating and performing custom assays for novel clinical biomarkers, immunogenicity testing, cell-based assays, mass spectrometry, and multiplex testing.
PBI is headquartered in Seattle, Washington, and its common stock trades on the OTC Bulletin Board under the symbol “PBMC”. For more information about PBI, visit the company’s website at www.pacbio.com.
This press release includes forward-looking statements including, but not limited to, the following: results of business development activities; future growth; and the viability and acceptance of the Company’s biomarker services. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, the following: the Company’s ability to enter into contracts for its laboratory testing or biomarker services; client changes or early terminations of studies; variability in backlog; the success of marketing and business development efforts, and competitive factors; the Company’s ability to manage growth; and other risks and uncertainties set forth in periodic filings with the U.S. Securities and Exchange Commission (including Form 10-K for the year ended June 30, 2009).
Pacific Biomarkers, Inc.
Ron Helm, CEO
The Investor Relations Group